Table 1 Survival analysis using Cox regression.

From: Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman’s disease: renal function is an important prognostic factor

 

Risk factors

Univariate analysis

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

Demographic characteristics

Age at CD diagnosis (years)

1.03 (0.99–1.08)

0.15

  
 

Gender, male (n)

0.29 (0.08–1.06)

0.06

0.32 (0.09–1.16)

0.08

 

HV variate (n)

0.90 (0.29–2.76)

0.85

  
 

The same side of the diaphram (n)

0.04 (0.00–42.18)

0.36

  
 

*Chronic diseases (n)

1.06 (0.29–3.85)

0.94

  
 

Hepatitis virus infection (n)

1.44 (0.19–11.08)

0.73

  
 

Prior history of TB (n)

4.51 (1.23–16.47)

0.02

2.66 (0.67–10.55)

0.16

 

Development delay (n)

0.05 (0.00–8073.10)

0.62

  
 

POEMS (n)

3.03 (1.01–9.04)

0.047

2.01 (0.55–7.37)

0.29

 

ECOG ≥ 1

25.98 (0.02–33441.67)

0.37

  

Symptoms & signs

B symptom (n)

5.05 (0.65–38.98)

0.12

  
 

**Generalized symptoms (n)

1.00 (0.13–7.71)

1.00

  
 

Shortness of breath (n)

2.15 (0.72–6.43)

0.17

  
 

Rash (n)

1.97 (0.66–5.87)

0.22

  
 

Adenopathy (n)

2.79 (0.36–21.48)

0.33

  

System involvement

***eGFR< 60 ml/min (n)

4.89 (1.63–14.73)

0.005

4.60 (1.50–14.12)

0.008

 

Nephrotic syndrome (n)

0.05 (0.000–6256.44)

0.61

  
 

Pulmonary involvment (n)

1.51 (0.49–4.65)

0.47

  
 

Paraneoplastic pemphigus (n)

1.88 (0.24–14.68)

0.55

  

Laboratory tests

WBC (10^9/L)

1.10 (0.94–1.29)

0.22

  
 

Hb (g/L)

1.01 (0.99–1.03)

0.21

  
 

Platelet (10^9/L)

1.00 (0.99–1.00)

0.90

  
 

Positive urine protein (n)

0.78 (0.23–3.05)

0.79

  
 

Positive fecal occult blood (n)

2.84 (0.36–22.32)

0.32

  
 

Serum albumin (g/L)

0.94 (0.87–1.02)

0.16

  
 

Tbil (umol/L)

0.97 (0.82–1.14)

0.68

  
 

ALP (U/L)

0.99 (0.98–1.01)

0.28

  
 

LDH (U/L)

1.00 (0.99–1.01)

0.81

  
 

hsCRP (mg/L)

0.99 (0.97–1.01)

0.19

  
 

ANA positive (n)

0.03 (0.00–24.59)

0.32

  
 

HbsAg positive (n)

1.82 (0.23–14.07)

0.57

  
 

HCV positive (n)

0.05 (0.00–7145.0)

0.80

  
 

EBV–DNA positive (n)

0.04 (0.00–12940.0)

0.75

  
 

CMV–DNA positive (n)

0.04 (0.00–12940.0)

0.75

  
 

M–protein positive (n)

2.08 (0.70–6.21)

0.19

  
  1. CD, Castleman’s disease; HV, hyaline–vascular; TB, tuberculosis; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; Hb, hemoglobin; Tbil, total bilirubin; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; hsCRP, hypersensitive c-reactive protein; ANA, anti-nuclear antibodies; HbsAg, hepatitis B surface antigen; HCV, hepatitis C; EBV, Epstein-Barr Virus; CMV, cytomegalovirus.
  2. *Chronic disease: hypertension, diabetes, coronary heart disease, chronic liver disease, chronic kidney disease; **B symptom: fever, night sweats, weight loss; ***Generalized symptom: fatigue, malaise, appetite, pain; ****eGFR: estimated glomerular filtration rate with Modification of Diet in Renal Disease (MDRD) equation.
Back to article page